Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity [Phase 3]

View source ↗

Summary

An Amgen-sponsored Phase 3 trial evaluating the efficacy and safety of Dazodalibep for Sjögren's syndrome with moderate-to-severe systemic disease activity. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjögren Syndrome

Drugs mentioned

• Dazodalibep (dazodalibep)

Snippet

Sponsor: Amgen | Conditions: Sjogren's Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING